Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 17)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
2 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
3 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
4 |
|
Vaccines |
|
Phase 2 |
|
|
|
5 |
|
Aluminum sulfate |
Approved |
Phase 1 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
6 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
7 |
|
Immunoglobulin G |
|
Phase 1 |
|
|
|
8 |
|
Antibodies, Blocking |
|
Phase 1 |
|
|
|
9 |
|
gamma-Globulins |
|
Phase 1 |
|
|
|
10 |
|
Rho(D) Immune Globulin |
|
Phase 1 |
|
|
|
11 |
|
Amphotericin B |
Approved, Investigational |
|
|
1397-89-3 |
5280965 |
Synonyms:
ABBR amb
ABELCET
Ambisome
Amfotericina b
AMOPHOTERICIN B
AMPH-b
Amphocil
AMPHO-MORONAL
Amphortericin b
Amphotec
AMPHOTERCIN B
Amphotericin
AMPHOTERICIN B
Amphotericin b cholesterol dispersion
Amphotericin b colloidal dispersion
|
AMPHOTERICIN B LIPID COMPLEX
AMPHOTERICIN B LIPOSOMAL COMPLEX
Amphotericine b
AMPHOTÉRICINE B
Amphotericinum b
AMPHOTERICITIN B
AMPHOTREICIN B
AMPOTERICIN B
APT370
C-AMB
FUNGILIN
FUNGILIN IN ORABASE
Fungizone
Liposomal amphotericin b
NSC-527017
|
|
12 |
|
Streptomycin |
Approved, Vet_approved |
|
|
57-92-1 |
19649 |
Synonyms:
[2-Deoxy-2-(dimethylamino)-a-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-a-L-lyxofuranosyl]-(1->4)-{n',n'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
[2-Deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{n',n'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
[2-Deoxy-2-(dimethylamino)-α-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-α-L-lyxofuranosyl]-(1->4)-{n',n'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine}
2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-a-L-glucopyranosyl)-3-C-formyl-b-L-lyxopentanofuranoside
2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside
2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-α-L-glucopyranosyl)-3-C-formyl-β-L-lyxopentanofuranoside
CEPA brand OF streptomycin sulfate
CHEMFORM
Clariana brand OF streptomycin sulfate
ESTREPTOMICINA
Estreptomicina cepa
Estreptomicina clariana
Estreptomicina normon
Fatol brand OF streptomycin sulfate
GEROX
Grünenthal brand OF streptomycin sulfate
Kantrex
Normon brand OF streptomycin sulfate
NSC-14083
Panpharma brand OF streptomycin sulfate
Sanavita brand OF streptomycin sulfate
|
SM
Streomycin
STREPCEN
Strepto fatol
Strepto hefa
Strepto-fatol
Strepto-hefa
STREPTOMICINA
STREPTOMYCIN
Streptomycin a sulfate
Streptomycin grünenthal
Streptomycin sesquisulfate hydrate
Streptomycin sesquisulphate hydrate
Streptomycin sulfate
Streptomycin sulfate (2:3) salt
Streptomycin sulphate
Streptomycin, sulfate salt
Streptomycine panpharma
STREPTOMYZIN
Wernigerode brand OF streptomycin sulfate
|
|
13 |
|
L-Glutamine |
Approved, Investigational, Nutraceutical |
|
|
56-85-9 |
5961 |
Synonyms:
(2S)-2,5-Diamino-5-oxopentanoate
(2S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
(2S)-2-Amino-4-carbamoylbutanoate
(2S)-2-AMINO-4-CARBAMOYLBUTANOIC ACID
(S)-2,5-Diamino-5-oxopentanoate
(S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
[<sup>14</sup>C]-glutamine
[<sup>3</sup>H]-glutamine
2-Aminoglutaramic acid
Cebrogen
D Glutamine
D-Glutamine
ENDARI
FEMA NO. 3684
gamma-Glutamine
Glavamin
GLN
Glumin
Glutamate 5-amide
Glutamate amide
GLUTAMIC ACID 5-AMIDE
GLUTAMIC ACID AMIDE
Glutamina
GLUTAMINE
L Glutamine
L-(+)-GLUTAMINE
|
L-2-Aminoglutaramate
L-2-AMINOGLUTARAMIC ACID
L-2-Aminoglutaramidic acid
Levoglutamid
Levoglutamida
LEVOGLUTAMIDE
Levoglutamidum
Levoglutamina
L-Glutamate g-amide
L-Glutamate gamma-amide
L-Glutamate γ-amide
L-Glutamic acid 5-amide
L-Glutamic acid g-amide
L-GLUTAMIC ACID GAMMA-AMIDE
L-GLUTAMIC ACID Γ-AMIDE
L-Glutamid
L-Glutamide
L-GLUTAMIN
L-GLUTAMINE
L-GLUTAMINSAEURE-5-AMID
L-GLUTAMINSÄURE-5-AMID
NSC-27421
NUTRESTORE
Polyglutamine
Q
Stimulina
|
|
14 |
|
Pyruvate |
|
|
|
|
|
15 |
|
Penicillins |
|
|
|
|
|
16 |
|
Gentamicins |
|
|
|
|
|
17 |
|
Liposomal amphotericin B |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 55)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study |
Recruiting |
NCT03037164 |
Phase 3 |
|
2 |
VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents |
Completed |
NCT03110770 |
Phase 2 |
|
3 |
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas |
Active, not recruiting |
NCT04917861 |
Phase 2 |
|
4 |
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Day 1 and 29 and of a Single Booster Dose of PIZV Administered at 6 Months Post Dose 2 in Healthy Subjects Aged 18 to 65 Years in the US |
Not yet recruiting |
NCT05469802 |
Phase 2 |
|
5 |
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region |
Completed |
NCT03014089 |
Phase 1 |
|
6 |
Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area |
Completed |
NCT03008122 |
Phase 1 |
|
7 |
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults |
Completed |
NCT02996461 |
Phase 1 |
|
8 |
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers |
Completed |
NCT02996890 |
Phase 1 |
|
9 |
Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects |
Completed |
NCT02952833 |
Phase 1 |
Saline |
10 |
A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects |
Completed |
NCT02963909 |
Phase 1 |
|
11 |
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years |
Completed |
NCT03343626 |
Phase 1 |
Placebo |
12 |
Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate 2 Doses of 3 Sequentially Escalating Cohort of BBV121 in Healthy Adult Dengue Sero-Negative and Dengue Sero-Positive Volunteers |
Completed |
NCT04478656 |
Phase 1 |
|
13 |
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP |
Completed |
NCT04033068 |
Phase 1 |
|
14 |
A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years |
Completed |
NCT03425149 |
Phase 1 |
|
15 |
Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers |
Completed |
NCT03624946 |
Phase 1 |
|
16 |
Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults |
Completed |
NCT03611946 |
Phase 1 |
|
17 |
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults |
Completed |
NCT04064905 |
Phase 1 |
|
18 |
A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults |
Completed |
NCT02937233 |
Phase 1 |
|
19 |
VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults |
Completed |
NCT02840487 |
Phase 1 |
|
20 |
Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers |
Completed |
NCT03443830 |
Phase 1 |
Tyzivumab |
21 |
A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers. |
Completed |
NCT04015648 |
Phase 1 |
|
22 |
Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) |
Recruiting |
NCT05123222 |
Phase 1 |
|
23 |
Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients |
Withdrawn |
NCT03776695 |
Phase 1 |
|
24 |
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua |
Unknown status |
NCT04182685 |
|
|
25 |
Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome |
Unknown status |
NCT03227601 |
|
|
26 |
Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 |
Unknown status |
NCT02810210 |
|
|
27 |
Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF |
Unknown status |
NCT03255369 |
|
|
28 |
Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy |
Unknown status |
NCT02943304 |
|
|
29 |
Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA |
Completed |
NCT03776903 |
|
|
30 |
Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome |
Completed |
NCT03330600 |
|
|
31 |
Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. |
Completed |
NCT03679728 |
|
|
32 |
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil |
Completed |
NCT03106714 |
|
|
33 |
Persistence of Zika Virus in Semen After Acute Infection |
Completed |
NCT02733796 |
|
|
34 |
Rescuing Neurodevelopment in Zika-Exposed Infants in Grenada |
Completed |
NCT04697147 |
|
|
35 |
Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors |
Completed |
NCT02794181 |
|
|
36 |
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection |
Completed |
NCT02979938 |
|
|
37 |
Prospective Cohort Study of HIV and Zika in Infants and Pregnancy |
Completed |
NCT03263195 |
|
|
38 |
Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy |
Completed |
NCT03393286 |
|
|
39 |
World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia |
Completed |
NCT03631719 |
|
|
40 |
Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia |
Completed |
NCT03206541 |
|
|
41 |
Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance) |
Completed |
NCT03188731 |
|
|
42 |
Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine |
Completed |
NCT03158233 |
|
|
43 |
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) |
Completed |
NCT02831699 |
|
|
44 |
Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 |
Completed |
NCT02916732 |
|
|
45 |
International Prospective Observational Cohort Study of Zika in Infants |
Completed |
NCT02856984 |
|
|
46 |
Pilot Study to Detect Zika Virus in Sperm |
Completed |
NCT02874456 |
|
|
47 |
The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy |
Completed |
NCT04118738 |
|
|
48 |
Adherence to Care for Children Born to Mothers With Laboratory Evidence of Confirmed or Possible Congenital Zika Virus Infection During Pregnancy. |
Recruiting |
NCT05041439 |
|
|
49 |
Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose. |
Recruiting |
NCT01099852 |
|
|
50 |
Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome |
Enrolling by invitation |
NCT04398901 |
|
|
|